Vertex Pharmaceuticals, a biotech known for its clinical development programmes in cystic fibrosis, has appointed a new chief medical officer in the form of Reshma Kewalramani.
She succeeds Jeffrey Chodakewitz, who will remain at the company as a senior advisor through early 2019.
Jeffrey Leiden, chairman, president and chief executive officer of Vertex, said: “Reshma’s depth of medical knowledge, paired with her experience and proven track record as a clinical leader at Vertex, makes her an ideal successor to Jeff.
“I look forward to working with her to continue to advance our clinical development pipeline in cystic fibrosis and other serious diseases.”
Prior to joining the biotech, Kewalramani served as vice president, head of the US medical organisation at Amgen, where she spent 12 years in various capacities.
She said: “It’s a privilege to work at a company with such a relentless focus on science and deep commitment to improving the lives of patients and their families.
“I am excited to assume the role of CMO and continue our important work to help more people with cystic fibrosis and other serious diseases alongside the talented team at Vertex.”